Jannik N. Andersen, Ph.D., is Chief Scientific Officer at Tango Therapeutics (NASDAQ: TNGX), where he leads research and drug discovery focused on oncology and translational science. His work integrates target validation, functional genomics, and small-molecule drug discovery, with an emphasis on precision medicine and synthetic lethality. Dr. Andersen has over two decades of experience across the translational research spectrum, including roles in academia, the biotech sector, and the pharmaceutical industry. Prior to joining Tango in 2019, he held scientific leadership positions at Xios and XTuit Pharmaceuticals and served as a director at both the Dana-Farber Cancer Institute and the Institute for Applied Cancer Science at MD Anderson Cancer Center. Earlier in his career, he contributed to oncology drug discovery efforts at Merck Research Laboratories and trained in drug development at Novo Nordisk. He holds an M.Sc. in Chemical Engineering from the Technical University of Denmark, an M.Sc. and Ph.D. in Human Biology from the University of Copenhagen and completed his doctoral research at Novo Nordisk. He was an Erasmus Scholar at Institut Polytechnique de Grenoble and conducted postdoctoral research at Cold Spring Harbor Laboratory, where he studied molecular mechanisms of signal transduction and their therapeutic implications in cancer.